IMS Capital Management Purchases New Holdings in Danaher Corporation $DHR

Key Points

• IMS Capital Management acquired a new position in Danaher Corporation, purchasing 10,668 shares valued at approximately $2,107,000 during the 2nd quarter.
• Analysts have a consensus rating of "Moderate Buy" on Danaher, with a consensus target price of $245.91, while UBS recently cut their target price from $240 to $225.
• Danaher announced a quarterly dividend of $0.32 per share, with the payment scheduled for October 31st, indicating a modest annualized payout of $1.28 and a yield of 0.7%.

IMS Capital Management purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 10,668 shares of the conglomerate's stock, valued at approximately $2,107,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Hills Bank & Trust Co grew its stake in shares of Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after buying an additional 53 shares in the last quarter. Sageworth Trust Co lifted its stake in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after acquiring an additional 54 shares during the last quarter. 1834 Investment Advisors Co. grew its position in shares of Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after acquiring an additional 54 shares during the period. Bruce G. Allen Investments LLC grew its position in shares of Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock valued at $92,000 after acquiring an additional 54 shares during the period. Finally, Rakuten Securities Inc. increased its stake in shares of Danaher by 33.3% during the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock worth $46,000 after purchasing an additional 56 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. UBS Group cut their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft dropped their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Barclays reiterated an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Royal Bank Of Canada set a $241.00 target price on Danaher in a report on Tuesday, September 2nd. Finally, Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $245.91.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $189.24 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm has a market cap of $135.50 billion, a price-to-earnings ratio of 40.26, a P/E/G ratio of 2.66 and a beta of 0.75. The stock's fifty day moving average price is $199.95 and its two-hundred day moving average price is $197.97. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the firm earned $1.72 earnings per share. The company's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.